Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betaine aldehyde
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Betaine aldehyde is a small molecule and a quaternary ammonium ion that serves as an intermediate in the metabolic pathway converting choline to betaine. It is involved in the metabolism of amino acids such as glycine, serine, and threonine. In humans and other organisms (including Escherichia coli and Aspergillus), it is produced during choline oxidation. Betaine aldehyde is converted to glycine betaine by the enzyme aldehyde dehydrogenase (EC 1.2.1.3). It has not been approved for pharmaceutical use but may be used experimentally or as a research chemical[1][2][4][5][6][8].
- Other names
- betaine aldehydeglycine betaine aldehydetrimethyl(2-oxoethyl)azaniumTrimethyl(formylmethyl)ammonium
02
Targets
PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on betaine aldehyde.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betaine aldehyde.